Department Home >
- Base >
- You are here
Network for Translation Research in Optical Imaging
The National Cancer Institute (NCI) has instituted a cooperative agreement (U54) award to establish a Specialized Research Resource Center that will participate as a member of a network of inter-disciplinary, inter-institutional research teams for the purpose of supporting translational research in optical imaging and/or spectroscopy in vivo. The network is named the "Network for Translational Research: Optical Imaging" (NTROI) and will operate under the guidance of an NCI Steering Committee (SC). About the NTROIThe objective is to accelerate the pace of translational research by developing a consensus process to improve methods for system integration, optimization and validation of next-generation in vivo optical imaging and/or spectroscopy methods and technologies, including contrast agents. Investigators are encouraged to include in vivo molecular imaging methods that give information about molecular events in cells or the extra-cellular milieu. The research scope includes feasibility studies for the detection of pre-cancerous lesions, cancer detection and diagnosis, and measurement or prediction of response to therapy. The "Philadelphia Team" of NTROI investigators is asking fundamental questions with respect to cancer development, lymph node matastases, tumor angiogenesis, and understanding therapeutic response and toxicity of chemotherapy. The Team is developing molecular optical imaging techniques and probes to address these fundamental questions in animal models and is employing technology development, optimization of imaging and independent validation using a variety of imaging techniques including optical imaging. The assembled group of investigators is multidisciplinary and multi-institutional, and includes partners from Idustry. Participating institutions include the University of Pennsylvania School of Medicine including the Department of Medicine (Hematology/Oncology), the Department of Radiology, the Children's Hospital of Philadelphia, and the Fox Chase Cancer Center. The focus and motivating force of this Team are the biological questions driving the required molecular imaging techniques, and this represents a major strength of the Philadelphia consortium. The experimental plan is highly translational with specific goals in mind including early detection of colonic neoplasms, early detection of lymphatic spread, non-invasive imaging of angiogenesis and its correlates hypoxia, hypoglycemia and blood flow, and early detection of specific markers of therapeutic response and toxicity. Efforts are in place to develop imaging of metabolic correlates, to make comparisons with other non-invasive methods, and to develop non-invasive optical imaging methods and probes. There is an effort to develop novel therapeutics to treat polyps, to inhibit angiogenesis and to specifically increase tumor apoptosis using available reagents and compounds as well as through high-throughput chemical library screening using specific molecular imaging algorithms to facilitate the identification of novel and effective agents for cancer therapy. Efforts are in place to develop interactions with industry to bring new technologies or models to the consortium, and efforts are in place to identify and fund projects that are in a Developmental phase. The proposed research directions are likely to have significant impact on the national effort in translational research to develop better methods for early detection, to better predict therapeutic outcome, and to identify novel therapeutic agents and combinations for the treatment of cancer patients. Contact UsPlease direct all inquiries about the Philadelphia NTROI to: Wafik S. El-Deiry, MD, PhD
|
Principal Investigator: 